Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011
10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011